Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Dec. 2025,
MindMaze Therapeutics Holding paidCHF0.00 Mil more to buy back shares than it received from issuing new shares.
It receivedCHF0.00 Mil from issuing more debt.
It paidCHF0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedCHF0.00 Mil from paying cash dividends to shareholders.
It receivedCHF13.28 Mil on other financial activities.
In all, MindMaze Therapeutics HoldingearnedCHF13.28 Mil on financial activities for the
six
months ended in Dec. 2025.
MindMaze Therapeutics Holding (XSWX:MMTX) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
MindMaze Therapeutics Holding's issuance of stock for the
six
months ended in Dec. 2025 was CHF0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
MindMaze Therapeutics Holding's repurchase of stock for the
six
months ended in Dec. 2025 was CHF0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
MindMaze Therapeutics Holding's net issuance of debt for the
six
months ended in Dec. 2025 was CHF0.00 Mil.
MindMaze Therapeutics Holding receivedCHF0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
MindMaze Therapeutics Holding's net issuance of preferred for the
six
months ended in Dec. 2025 was CHF0.00 Mil.
MindMaze Therapeutics Holding paidCHF0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
MindMaze Therapeutics Holding's cash flow for dividends for the
six
months ended in Dec. 2025 was CHF0.00 Mil.
MindMaze Therapeutics Holding receivedCHF0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
MindMaze Therapeutics Holding's other financing for the
six
months ended in Dec. 2025 was CHF13.28 Mil.
MindMaze Therapeutics Holding receivedCHF13.28 Mil on other financial activities.
MindMaze Therapeutics Holding Cash Flow from Financing Related Terms
MindMaze Therapeutics Holding Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding Cash Flow from Financing Chart
MindMaze Therapeutics Holding Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 was CHF13.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of CHF13.01 Mil mean?
MindMaze Therapeutics Holding (XSWX:MMTX) has a Cash Flow from Financing of CHF13.01 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's Cash Flow from Financing too high?
MindMaze Therapeutics Holding's current Cash Flow from Financing is CHF13.01 Mil. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Cash Flow from Financing compare to VRTX and REGN?
MindMaze Therapeutics Holding's Cash Flow from Financing of CHF13.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current Cash Flow from Financing is CHF13.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current Cash Flow from Financing of CHF13.01 Mil. The current Cash Flow from Financing is CHF13.01 Mil. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current Cash Flow from Financing is CHF13.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding Business Description
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score
Get the complete analysis for XSWX:MMTX
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MMTX has been successfully added to your 
